4DMedical Ltd
ASX:4DX

Watchlist Manager
4DMedical Ltd Logo
4DMedical Ltd
ASX:4DX
Watchlist
Price: 1.9 AUD 3.26% Market Closed
Market Cap: 972.1m AUD

4DMedical Ltd
Investor Relations

4DMedical Ltd. is a software technology company, which commercializes four-dimensional lung imaging platform called XV Technology. The company is headquartered in Melbourne, Victoria. The company went IPO on 2020-08-07. The firm is focused on development of a non-invasive respiratory imaging solution using four-dimensional imaging. The firm's XV Technology is a four-dimensional lung imaging technology that utilizes mathematical models and algorithms to convert X-ray scans into quantitative data for physicians to manage patients with respiratory diseases and diseases of the lung. The XV Technology is accessible through a cloud-based software as a service (SaaS) platform that integrates with existing hospital equipment. The XV Technology Lung Ventilation Analysis Software (XV LVAS Ventilation) provides a non-invasive way of understanding regional lung motion and airflow. The company enables physicians to detect areas of high and low ventilation from all parts of the lung, in all phases of the breath.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q2 2025
Call Date
Mar 3, 2025
AI Summary
Q2 2025

Revenue Growth: 4DMedical reported a 16.5% half-to-half revenue increase, with a $6 million recurring revenue run rate, though recent contract wins are not yet fully reflected in these numbers.

Cost Management: Operating expenditure dropped by 11% half-on-half, and management says the company is well past its peak spending.

Capital Raising: The company is completing a $12.5 million placement and SPP, structured to potentially bring in $30 million in total, aimed at funding the business through to breakeven.

Philips Partnership: The Philips reseller agreement is expected to bring contracts and meaningful revenue before June 30, with Philips' 250 salespeople now selling 4DMedical products.

Product Momentum: Recent FDA approval and $650 Medicare reimbursement for IQ-UIP, as well as growth in scan volumes, sites, and average price per scan, are driving momentum.

Australia and U.S. Trends: U.S. revenue is rising significantly; Australian revenue appeared to drop due to a legacy contract rolling off, but underlying business there has grown by 40% recently.

VQ Product Launch: The upcoming VQ product is positioned as a superior, logistically easier alternative to nuclear medicine VQ scans, targeting a $1 billion U.S. market.

Key Financials
Revenue
$6 million recurring run rate
Sites
over 300 sites
Capital Raised
$12.5 million (minimum placement and SPP); potentially $30 million total
IQ-UIP Reimbursement
$650 per scan (Medicare reimbursement)
Earnings Call Recording
Other Earnings Calls
2025

Management

Dr. Andreas Fouras M.A.I.C.D., Ph.D.
Founder, MD, CEO & Director
No Bio Available
Mr. Simon Glover
Chief Financial Officer
No Bio Available
Mr. John Andrew Livingston BAppSci, GradCertBus, GradDipHSc
Strategic Advisor & Executive Director
No Bio Available
Mr. Matt Tucker
Chief Commercial Officer
No Bio Available
Ms. Naomi Lawrie
Company Secretary & General Counsel
No Bio Available
Dr. Aidan Jamison B.E., Ph.D.
Senior Vice President of Engineering
No Bio Available
Ms. Rachael Tenkaten
Senior Vice President of Product
No Bio Available
Dr. Greg T. Mogel M.D.
Chief Medical Officer
No Bio Available
Mr. David Hannes B.S., M.B.A.
Senior Vice President of Global Business Development
No Bio Available

Contacts

Address
VICTORIA
Melbourne
5/468 St. Kilda Road
Contacts
+61395455940.0
4dmedical.com